Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

281. Motesanib diphosphate in progressive differentiated thyroid cancer. Full Text available with Trip Pro

Motesanib diphosphate in progressive differentiated thyroid cancer. The expression of vascular endothelial growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor clinical outcome. Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT.In an open-label, single-group, phase 2 study, we treated 93 patients who had progressive, locally advanced (...) or metastatic, radioiodine-resistant differentiated thyroid cancer with 125 mg of motesanib diphosphate, administered orally once daily. The primary end point was an objective response as assessed by an independent radiographic review. Additional end points included the duration of the response, progression-free survival, safety, and changes in serum thyroglobulin concentration.Of the 93 patients, 57 (61%) had papillary thyroid carcinoma. The objective response rate was 14%. Stable disease was achieved

2008 NEJM

282. Maternal use of thyroid hormones in pregnancy and neonatal outcome (Abstract)

Maternal use of thyroid hormones in pregnancy and neonatal outcome To describe neonatal outcome including the presence of congenital malformations in infants born to women substituted with thyroid hormones, and the maternal characteristics of these women.Register study based on prospectively collected data in relation to delivery.Swedish Health Registers.All pregnant women (n=848,468) and all infants born (n=861,989) in Sweden from 1 July 1995 to 31 December 2004.Women who reported the use (...) of thyroid hormones in early pregnancy or obtained a prescription for thyroid hormones later in pregnancy (n=9,866), as well as their infants (n=10,055) were identified from the Swedish Medical Birth Register. The reference population consisted of all women giving birth and their offspring during the same time interval.Neonatal outcome, malformations and maternal characteristics. Data were analyzed with adjustments for identified confounders.Women using thyroxine had an increased rate of pre-eclampsia

2008 EvidenceUpdates

283. Intraoperative nerve monitoring during thyroid surgery (IPG255)

Intraoperative nerve monitoring during thyroid surgery (IPG255) Overview | Intraoperative nerve monitoring during thyroid surgery | Guidance | NICE Intraoperative nerve monitoring during thyroid surgery Interventional procedures guidance [IPG255] Published date: March 2008 Share Save Guidance The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on intraoperative nerve monitoring during thyroid (...) surgery. Description The thyroid gland lies close to the vocal cords and the nerves that control movement of the vocal cords (recurrent laryngeal nerves). When surgery is performed on the thyroid gland, a nerve monitor is sometimes used during the operation with the aim of helping to prevent potential damage to the nerves. and for this guidance. Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising

2008 National Institute for Health and Clinical Excellence - Interventional Procedures

284. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy

EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy GUIDELINES EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy Michael Lassmann &Heribert Hänscheid & Carlo Chiesa &Cecilia Hindorf &Glenn Flux & Markus Luster Published online: 20 May 2008 # EANM 2008 (...) Abstract Introduction ThepurposeoftheEANMDosimetryCommit- tee Series on “Standard Operational Procedures for Pre- therapeutic Dosimetry” (SOP) is to provide advice to scientists and clinicians on how to perform pre-therapeutic and/ortherapeuticpatient-specificabsorbeddoseassessments. Material and Methods This particular SOP gives advice on how to tailor the therapeutic activity to be administered for systemic treatment of differentiated thyroid cancer (DTC) such that the absorbed dose to the blood does

2008 European Association of Nuclear Medicine

285. Guidelines for radioiodine therapy of differentiated thyroid cancer

Guidelines for radioiodine therapy of differentiated thyroid cancer GUIDELINES Guidelines for radioiodine therapy of differentiated thyroid cancer M. Luster &S. E. Clarke &M. Dietlein &M. Lassmann & P. Lind &W. J. G. Oyen &J. Tennvall &E. Bombardieri # EANM 2008 Abstract Introduction The purpose of the present guidelines on the radioiodine therapy (RAIT) of differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear Medicine (EANM) TherapyCommittee istoprovideadvice (...) to nuclear medicine clinicians and other members of the DTC-treating community on how to ablate thyroid remnant or treat inoperable advanced DTC or both employing large 131-iodine ( 131 I) activities. Discussion For this purpose, recommendations have been formulated based on recent literature and expert opinion regarding the rationale, indications and contraindications for these procedures, as well as the radioiodine activities and the administration and patient preparation techniques to be used

2008 European Association of Nuclear Medicine

286. Grand Rounds: Thyroid Disease and the Heart

Grand Rounds: Thyroid Disease and the Heart Grand Rounds: Thyroid Disease and the Heart – Clinical Correlations Search Grand Rounds: Thyroid Disease and the Heart September 24, 2008 4 min read Commentary by Sarika Modi MD, PGY-2 Dr. Irwin Klein MD, Professor of Medicine and Cell Biology, of North Shore University Hospital, gave grand rounds on “Thyroid Disease and the Heart” on September 17, 2008. He began his talk by giving an overview of the broad spectrum of cardiac manifestations seen (...) of the angina is thought to be vasospasm, similar to Prinzmetal’s angina and migraine headaches. 85% of thyroid hormone produced by the thyroid gland is in the form of T4, but the biologically active form is T3 which arises by peripheral deiodination in the liver and skeletal muscle. The cardiovascular effects of thyroid hormone include increased heart rate, increased ejection fraction, increased cardiac output (by 150-200%), muscular hypertrophy of the heart, and a fall in systemic vascular resistance. T3

2008 Clinical Correlations

287. Review: available evidence does not support a benefit for thyroid hormone replacement in adults with subclinical hypothyroidism Full Text available with Trip Pro

Review: available evidence does not support a benefit for thyroid hormone replacement in adults with subclinical hypothyroidism Review: available evidence does not support a benefit for thyroid hormone replacement in adults with subclinical hypothyroidism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: available evidence does not support a benefit for thyroid hormone replacement in adults with subclinical hypothyroidism

2008 Evidence-Based Medicine

288. Meta-analysis: prophylactic drainage and bleeding complications in thyroid surgery

Meta-analysis: prophylactic drainage and bleeding complications in thyroid surgery Meta-analysis: prophylactic drainage and bleeding complications in thyroid surgery Meta-analysis: prophylactic drainage and bleeding complications in thyroid surgery Kennedy SA, Irvine RA, Westerberg BD, Zhang H CRD summary This review concluded that there was insufficient evidence to recommend drainage in thyroid surgery and that drains may possibly have increased the risk of reoperation for bleeding (...) . The authors' conclusions appeared to reflect the evidence, but a lack of details on excluded studies and poor reporting in the review made the reliability of the findings unclear. Authors' objectives To assess the effectiveness of prophylactic drain placement in reducing adverse bleeding events in thyroid surgery. Searching MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews, ACP Journal Club, DARE, PREMEDLINE, OLDMEDLINE, CINAHL, BIOSIS

2008 DARE.

289. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer

An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

290. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors

A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

291. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors

A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

292. Fine-needle aspiration biopsy versus ultrasound-guided fine-needle aspiration biopsy: cost-effectiveness as a frontline diagnostic modality for solitary thyroid nodules Full Text available with Trip Pro

Fine-needle aspiration biopsy versus ultrasound-guided fine-needle aspiration biopsy: cost-effectiveness as a frontline diagnostic modality for solitary thyroid nodules Fine-needle aspiration biopsy versus ultrasound-guided fine-needle aspiration biopsy: cost-effectiveness as a frontline diagnostic modality for solitary thyroid nodules Fine-needle aspiration biopsy versus ultrasound-guided fine-needle aspiration biopsy: cost-effectiveness as a frontline diagnostic modality for solitary thyroid (...) for the initial diagnosis of solitary thyroid nodules. The authors concluded that the use of UG-FNAB was more cost-effective than traditional FNAB, with an incremental cost of $289 per additional correct diagnosis. The analysis appears to have been based on a valid methodology, although the clinical part was poorly reported. The authors’ conclusions appear to be valid. Type of economic evaluation Cost-effectiveness analysis Study objective The objective was to carry out a comparative cost-effectiveness

2008 NHS Economic Evaluation Database.

293. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis Full Text available with Trip Pro

Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis Cheung K, Roman S A, Wang T S, Walker H D, Sosa J A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of calcitonin screening in combination with current screening practices, in the authors' setting, for the evaluation of thyroid nodules. The authors concluded that the cost-effectiveness of calcitonin screening compared

2008 NHS Economic Evaluation Database.

294. Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis Full Text available with Trip Pro

Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis Dosiou C, Sanders G D, Araki S S, Crapo L M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of screening pregnant women for autoimmune thyroid disease. The authors concluded that screening all pregnant women in the first trimester was cost-effective compared with no screening. Overall, the methodology was appropriate and the methods and results were adequately reported. Given the scope of the analysis the authors

2008 NHS Economic Evaluation Database.

295. Thyroid autoimmunity at onset of type 1 diabetes as a predictor of thyroid dysfunction. Full Text available with Trip Pro

Thyroid autoimmunity at onset of type 1 diabetes as a predictor of thyroid dysfunction. Thyroid autoimmunity at onset of type 1 diabetes as a predictor of thyroid dysfunction. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 (...) selected item: 17372152 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2007 Jun;30(6):1611-2. Epub 2007 Mar 19. Thyroid autoimmunity at onset of type 1 diabetes as a predictor of thyroid dysfunction. 1 , , , , , . 1 Pediatric Department, Hospital Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. gcarreras

2007 EvidenceUpdates

296. Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia. (Abstract)

Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia. Extremely premature infants are at risk of transient hypothyroxinaemia in the first weeks after birth. These low thyroid hormone levels are associated with an increased incidence of neonatal morbidity, mortality and longer term developmental impairments. Thyroid hormone therapy might prevent these problems.To determine the evidence for thyroid hormone therapy in preterm infants with transient hypothyroxinaemia (low (...) thyroid hormone level, normal TSH) for improvement of neonatal outcomes and neurodevelopment.Searches were performed of The Cochrane Central Register of Controlled (CENTRAL, The Cochrane Library, Issue 1, 2006), MEDLINE (1966 - March 2006), PREMEDLINE (March 2006), EMBASE (1980 - March 2006), previous reviews including cross references, abstracts and conference proceedings, supplemented by requests to expert informants.Trials enrolling preterm infants with transient hypothyroxinaemia (low thyroid

2007 Cochrane

297. Management of Thyroid Cancer

Management of Thyroid Cancer Guidelines for the management of thyroid cancer Second edition British Thyroid Association Royal College of Physicians 2007ii Citation for this document: British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer (Perros P, ed) 2nd edition. Report of the Thyroid Cancer Guidelines Update Group. London: Royal College of Physicians, 2007. Copyright All rights reserved. No part of this publication may be reproduced in any (...) form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher. Copyright © 2007 Royal College of Physicians of London ISBN: 978-1-86016-309-8 Review date: 2012 BRITISH THYROID ASSOCIATION www.british-thyroid

2007 British Association of Endocrine and Thyroid Surgeons

298. Part I- Subclinical Thyroid Dysfunction: To Treat or Not to Treat?

Part I- Subclinical Thyroid Dysfunction: To Treat or Not to Treat? Part I- Subclinical Thyroid Dysfunction: To Treat or Not to Treat? – Clinical Correlations Search Part I- Subclinical Thyroid Dysfunction: To Treat or Not to Treat? July 31, 2007 5 min read | | One comment on “ Part I- Subclinical Thyroid Dysfunction: To Treat or Not to Treat? ” Comments are closed. Sites We Follow: Useful Links: Questions? Comments? Contact us! © New York University. All rights reserved. Electronic ISSN 1944

2007 Clinical Correlations

299. Part II- Subclinical Thyroid Dysfunction: To Treat or Not to Treat?

Part II- Subclinical Thyroid Dysfunction: To Treat or Not to Treat? Part II- Subclinical Thyroid Dysfunction: To Treat or Not to Treat? – Clinical Correlations Search Part II- Subclinical Thyroid Dysfunction: To Treat or Not to Treat? August 8, 2007 4 min read of this series In 2002, the American Association of Clinical Endocrinologists (AACE), the American Thyroid Association (ATA), and The Endocrine Society (TES) sponsored an evidence- based Consensus Development Conference with a panel (...) of thirteen experts to address unresolved issues about subclinical thyroid dysfunction. Though these sponsors agreed with many of the recommendations made by the consensus, they felt that they relied too heavily on evidence-based medicine that did not yet exist. Two years later, the AACE, TES, and ATA published their own consensus statement, pronouncing that they found their expert’s negative recommendations regarding general screening and treatment to be “based primarily on a lack of evidence for benefit

2007 Clinical Correlations

300. Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm": a critical appraisal of the evidence

Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm": a critical appraisal of the evidence Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm"? A critical appraisal of the evidence Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular (...) neoplasm"? A critical appraisal of the evidence Sanabria A, Carvalho AL, De Andrade VP, Rodrigo JP, Vartanian JG, Rinaldo A, Ikeda MK, Devaney KO, Magrin J, Soares FA, Ferlito A, Kowalski LP CRD summary This review found that galectin-3 had the potential to guide therapy decisions in patients with thyroid nodules, but that the quality of the available data was too poor to allow definitive conclusions. Limitations in the literature search, failure to assess study quality and lack of synthesis mean

2007 DARE.